Clozapine: A Clinical Review of Adverse Effects and Management

References

• Kessler RC, McGonagle KA, Zhao S. Nelson CB, Hughes M, Eshleman S. Wittchcn HU, Kendler KS: Lifetime 12-month prevalence of DSM-11I-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8–19
   Google Scholar
• Rosentein MJ, Milazzo-Sayre U. Manderscheid RW: Care of persons with schizophrenia: A statistical profile. Schizophr Bull 1989; 15:45–58
   Google Scholar
• Feltus MS, Gardner DM: Second generation antipsychotics for schizophrenia. Can J Clin Pharmacology 1999; 6:187–195
   PubMedGoogle Scholar
• Bartell PJ, Donenwirth K. etal.: Violence and schizophrenia: Clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law. 1995; 23:607–611
   Google Scholar
• Cohen SA, Underwood MT: The use of clozapine in a men-tally retarded and aggressive population. 1 Clin Psychiatry 1994; 55:440–444
   Google Scholar
• Gilman AG, Ruddon RW, Molinoff PB, Limberd LE. Hardman JG: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Health Professions Division; 1996
   Google Scholar
• Antipsychotic Agents: In: Baldessarini RJ, ed.; Chemother-apy in Psychiatry: Principles & Practice. Cambridge, MA: Harvard University Press, 1985:14–92
   Google Scholar
• Hunziker F, Kunzte F. Schmutz J: Uben em n 5-Stellung basischsubstituiente 5H Dibenzo (b,e)-1-4 diazepine. Hely Chim Acta 1963; 46:2337–2347
   Google Scholar
• Hippius H: The history of clozapine. Psychopharmacology. 1989; 99:S3–S5
   Google Scholar
• Nightingle SL: Approval of clozapine for refractory schizophrenia. JAMA 1990: 263:202
   Google Scholar
• Richelson E, Elson A: Antagonism of neurotransmitter re-ceptors of normal human brain in vitro. Eur J Pharmacol 1984; 103:197–214
   PubMed Web of Science ®Google Scholar
• Waddington JL: Neuroleptic/dopamine receptors. EurJ Phar-macol 1990; 183:106
   Google Scholar
• Meltzer HR, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of Dl-D2 and serotonin, PK I values. J Pharmacol Exp Ther 1989; 251:3238–3246
   Google Scholar
• Picker D, Owen RR, Litran RE, Konicki PE, Gutiennez R, Rappaport HM: Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345–353
   Google Scholar
• Litran RE, Hong WW, Weissman EM, Su TP, Potter WZ, Pickar D: Idazoxan, an alpha2 antagonist, augments fluphenazine in schizophrenic patients. A pilot study. J Clin Psychopharmacol 1993; 13:264–267
   Google Scholar
• Brown CS, Markowitz JS, Moore TR, Parker NG: Atypical antipsychotics: Part II - Adverse effects, drug interactions and costs. Ann Pharmacother 1999 33:210–217
   PubMed Web of Science ®Google Scholar
• Choe MG, Hsuan F, Honigfeld G, et al.: Single vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharmacol Res. 1990; 7:347–351
   Google Scholar
• Tandon R: Antipsychotic agents. In: Quitkin FM, Adams DC, Bowden CL, Heyer EJ, Rifkin A, Sellers EM, Tandon R, Taylor BP: eds. Current Psychotherapeutic Drugs, 2nd edn. Philadelphia: Current Medicine; 1998
   Google Scholar
• Sajatovic M: Clozapine for elderly patients. Pychiatric Ann. 2000; 30(3):170–174
   Google Scholar
• Kim BB: The Medical Letter Handbook of Adverse Drug Interactions. New York: The MedicalLetter; 2001: 206–209
   Google Scholar
• Young CR, Bowers, MB, Jr., Nlazure CM: Management of the adverse effects of clozapine. Schizophr Bull 1998; 24(3): 381–390
   PubMed Web of Science ®Google Scholar
• Gerson SL: G-CSF and the management of clozapine inducedagranulocytosis. J Clin Psychiatry 1994; 55(Suppl B):139–142
   Google Scholar
• Lieberman JA, Yunis J, Egen E. Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine induced agranu-locytosis. Arch Gen Psychiatry 1990; 47:945–948
   Google Scholar
• Alvir JN1, Lieberman JA: Agranulocytosis: Incidence and risk factors. J Clin Psychiatry 1994; 55(Suppl B):137–138
   Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis-Incidence and risk factors in the United States. N Eng J Med 1993; 329:162–167
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Kane JM, and Johns CA: Clozapine: Guide-lines for clinical management. J Clin Psychiatry 1989; 50:329–338
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Safferman AZ. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr Q 1992; 63:51–70
   PubMedGoogle Scholar
• Lieberman JA: Maximizing clozapine therapy: Managing side effects. J Clin Psychiatry. 1998:59 (Suppl 3): 38–43
   PubMedGoogle Scholar
• Honingfeld O, Arellano F, Sethi J. Bianchini A, Schein Jr Reducing clozapine-related morbidity and mortality: 5 years experience with the Clozaril National Registry [Abstract]. J Clin Psychiatry 1998; 59\(Supp 1 ) 3: 3–7
   Google Scholar
• Silver JN1, Yudofsky SC, Jurowitz GI: Psychopharmacology and electroconvulsive therapy. In: Hales RE, Yudofsky SC, Talbott JA, ed., The American Psychiatric Press Textbook of Psychiatry 2nd edn. Washington, DC. American Psychiatric Press, 1994: p. 920
   Google Scholar
• Krupp P. Barnes P: Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology 1989; 99:S118–S121
   Google Scholar
• Bastani B, Alphs LD, Meltzer HY. Development of the Clozaril Patinet Management System [Abstract]. Psy-chopharmacology 1989; 99(Suppl):S122–S125
   Google Scholar
• Friedberg JW, Frankenburg FR, Burk J, Johnson W: Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry 1995; 7:97–98
   PubMedGoogle Scholar
• Chatterton R: Eosinophilia after commencement of clozap-Me treatment. Aust NZ J Psychiatry 1997; 31:874–876
   PubMed Web of Science ®Google Scholar
• Tihonen J, Paanila J: Eosinophilia associated with clozapine. Lancet 1992; 399:488
   Google Scholar
• Banov MD, Tohen M, Friedberg J: High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54:466–469
   PubMed Web of Science ®Google Scholar
• Barbui C, Campomori A, Bonati M: Clozapine and blood dyscrasias different from agranulocytosis [Letter]. Can J Psy-chiatry 1997; 42(9):981–982
   Google Scholar
• Devinsky O, Pacia SV: Seizures during clozapine therapy. J Clin Psychiatry 1994; 55(9, Supp1 B): 153–156
   Google Scholar
• Hill D: The relationship between schizophrenia and epilepsy. Folia Psychiat Neurol Neurochir 1948; 51:95–111
   Google Scholar
• Notkin J: Epileptic manifestations in the group of schizophrenic and manic-depressive psychoses. J Nerv Ment Dis 1929; 69:494–521
   Google Scholar
• Toth P, Frankenburg FR: Clozapine and seizures: A review. Can J Psychiatry 1994; 39:236–238
   PubMed Web of Science ®Google Scholar
• Devinsky O, Honigfeld G, Patin Clozapine-related seizures. Neurology 1992; 41:369–371
   Google Scholar
• Helwick CA: Review .of clozapine therapy finds more ADRs than expected. Pharmacy Practice News 1992; March 1, p.7
   Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: A double-blind compari-son with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796
   PubMed Web of Science ®Google Scholar
• Claghorn J, Honigfeld G, Abuzzahab GS, Wang R, Steinbook R, Tuason V, Klerman G: The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377–384
   PubMed Web of Science ®Google Scholar
• Schmauss M. Wolff R. Erfurth A, Rather E: Tolerability of long term clozaril treatment. Psychopharmatology (Berl) 1989; 99:S105–S108
   Google Scholar
• Haller E, Binder RL: Clozapine and seizures. Am J Psychiatry 1990; 147:1069–1071
   PubMed Web of Science ®Google Scholar
• Itil TM, Soldatos C: Epileptogenic side-effects of psy-chotropic drugs: Practical recommendations. JAMA 1980; 244:1460–1463
   PubMed Web of Science ®Google Scholar
• Karper LP. Salloway SP, Seibyl JP, et al.: Prolonged postic-tal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992; 4:454–457
   PubMedGoogle Scholar
• Liukkonen J, Koponen HJ, Nousiainen U: Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment. Psychiatry Res 1992; 44:107–112
   PubMedGoogle Scholar
• Gouzoulis E, Grunze H, Bardeleben UV: Myoclonic epileptic seizures during clozapine treatment: A report of three cases. Ear Arch Psychiatry Neurol Sci 1991; 240:370–372
   Google Scholar
• Gouzoulis E, Ozdaglar A, Kasper J: Myoclonic seizures fol-lowed by grand mal seizures during clozapine treatment [Letter]. Am J Psychiatry 1993; 150:1128
   PubMedGoogle Scholar
• Tiihonen J. Nousiainen U, Hakola P. Leinonen E. Tuunainen A. Mervalla E. Paanila Jr EEG abnormalities associated with clozapine treatment [Letter]. Am J Psychiatry 1991; 148:1406
   Google Scholar
• Isermann H. Haupt R: Auffallige EEG-Veranderungen unter Clozapin-Behandlung bei paranoid-halluzinatorischen. Psy-chosen Nervenarzt 1976; 47:268
   Google Scholar
• Baldessarini RJ, Frankenburg FR: Clozapine: A novel an-tipsychotic agent. New Engl J Med 1991; 324:746–754
   PubMed Web of Science ®Google Scholar
• Kugler J. Lorenzi E, Spatz R, et al.: Drug-induced paroxysmal EEG activities. Pharmacopsychiatry 1979; 12:165–172
   Google Scholar
• Roubicek J, Major I: EEG profile and behavioral changes after a single dose of clozapine in normals and schizophrenics. Biol Psychiatry 1977; 12:613–633
   PubMed Web of Science ®Google Scholar
• Malow BA, Reese KB, Sato S, Bogard PJ, Malhotra AK, Su TP, Pickar D: Clozapine, myoclonus, and EEG abnormalities [Abstract]. Epilepsia 1993; 34(Suppl 6):129
   Google Scholar
• Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; 99(Suppl 99):S97–S100
   Google Scholar
• Szymanski S. Jody D, Leipsig R, Masiar S. Lieberman N: An-ticholinergic delirium caused by retreatment with clozapine [Letter]. Am I Psychiatry 1992; 148:1752
   Google Scholar
• Schuster?, Gabriel E, Kufferle B, Strobl G, Karobuth M: Re-versal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10:437–441
   Google Scholar
• Stanilla JK, Leon J, Simpson GM: Clozapine withdrawal re-sulting in delirium with psychosis: A report of three cases. J Clin Psychiatry 1997; 58(6):252–255
   Google Scholar
• Simpson GM, Varga E: Clozapine: A new antipsychotic agent. Curr Therapeut Res 1974; 16:679–686
   Google Scholar
• Simpson GM, Lee JH, Shrivastava RK: Clozapine in tardive dyskinesia. Psychopharmacology 1978; 56:75–80
   PubMed Web of Science ®Google Scholar
• Panteleeva GP, Tsutsul Kovskaya MY, Belyaev BS, et al.: Clozapine in the treatment of schizophrenic patients; An international multi-center trial. Clin 'Ther 1987; 10:57–68
   Google Scholar
• Juul Povlsen U, Noring U, Fog R: Tolerability and therapeu-tic effect of clozapine. Acta Psychiatr Scand 1985; 71:176–185
   Google Scholar
• Safferman AZ, Lieberman AJ, Kane JM: Syzmanski S. Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17(2):247–261
   Google Scholar
• - Cohen S: Sedation: In: Yesavage J, ed. Clozapine: A Com-pendium of Selected Readings. Stanford, CA: Sandoz Phar-maceutical; 1992: 132–133
   Google Scholar
• Burke M, Sebastian CS: Treatment of clozapine sedation [Letter]. Am J Psychiatry 1993; 150:127
   Google Scholar
• Meltzer HY: Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. Washington, DC: American Psychi-atric Press.; 1995: 631–639
   Google Scholar
• Baker RW, Chengappa KN, Baird JW, Steingard MD, Christ MA, Schooler NR: Emergence of obsessive-compulsive symptoms during treatment with clozapine. J Clin Psychia-try 1992; 53(12):439–442
   Google Scholar
• Levkovitch Y. Kronnenberg Y, Gaoni B: Can clozapine trig-ger OCD? [Letter]. J Am Acacl of Child Adolesc Psychiatry 1995; 34(3):263
   Google Scholar
• Cassidy SL, Thaker GK: Addition of duoxetine to clozapine. Am J Psychiatry 1993; 149:1900–1901
   Google Scholar
• Patel B, Tendon R: Development of obsessive-compulsive symptoms during clozapine treatment [Letter]. Am J Psychi-atry 1993; 150(5):836
   Google Scholar
• Tsai G, Cristomo G, Rosenblatt ML, Stern TA: Neurolep-tic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91–95
   PubMedGoogle Scholar
• Pope FIG Jr, Cole JO, Choras PT Fulwiler CE: Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv IvIent Dis 1986; 177(8):493–495
   Google Scholar
• Karagianis IL, Phillips LC, Hogan KR LeDrew KK: Clozapine-associated neuroleptic malignant syndrome: Two new cases and a review of the literature. Ann Pharmacother 1999; 33:623–630
   PubMed Web of Science ®Google Scholar
• Campellone IV, McCluskey LF, Greenspan D: Fatal outcome from neuroleptic malignant syndrome associated with clozap-ine. Neuropsychiatry Neuropsychol Behav Neurol 1995; 8:70–73
   Google Scholar
• Hasan S. Buckley?: Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry 1998; 155(8):1113–1116
   Google Scholar
• Sachdev P. Kurk J, Kneebone M, Kissane D: Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases. J Clin Psychopharmacol 1995; 15(5):365–371
   Google Scholar
• Rosebush?, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am .1 Psychiatry 1989; 146:717–725
   Google Scholar
• Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clinic North Am 1993; 77:185–202
   PubMed Web of Science ®Google Scholar
• Yamawaki S. Mono M, Kazamatsuri G, et al.: Clinical evalu-ation and effective usage of dantrolente sodium in neurolep-tic malignant syndrome. Kiso to Rinsyou (Clinical Reports). 1993; 27:1045–1066
   Google Scholar
• Fricchione G, Bush G,Fosdar M, et al.: Recognition and treat-ment of the catatonic syndrome. J Intensive Care Med 1997; 12:135–147
   Google Scholar
• Scheftner WA, Shulman RB: Treatment choice in neuroleptic malignant syndrome. Convul Ther 1992; 8:267–279
   PubMedGoogle Scholar
• Marinkovic D, Timtijevic I, Babinski T, Totic S, Paunovic VR: The side-effects of clozapine: A four year follow-up study. Prog Neuropsychopharmacol 1994; 18:537–544
   Google Scholar
• Cohen BM, Keck PE, Satlin A, Cole JO: Prevalence and severity of akathisia in patients on clozapine. Biol Psychia-try 1991; 29:1215–1219
   PubMed Web of Science ®Google Scholar
• Safferman AZ, Lieberman JA, Pollack S. Kane JM: Akathisia and clozapine treatment [Letter]. J Clin Psychopharmacol 1993; 13:286–287
   Google Scholar
• Wirshing WC, Phelan CK, Van Putten T, Marder SR, Engel J: Effects of clozapine on treatment-resistant akathisia and con-comitant tardive dyskinesia [Letter]. J Clin Psychopharmacol 1990; 10:371–373
   PubMed Web of Science ®Google Scholar
• Levin H, Chengappa KNR, Kambhamati RK, Mahdavi N, Ganguli R: Should treatment refractory akathisia be an in-dication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53:248–251
   Google Scholar
• Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM: Myoclonus in patients treated with clozapine: A case series. J Clin Psychiatry 1995; 56:418–422
   PubMed Web of Science ®Google Scholar
• Berman I, Zalma A, Durand CJ, Green Al: Clozapine. induced myoclonic jerks and drop attack [Letter]. J Clin Psy-chiatry 1992; 53:329–330
   Google Scholar
• Meltzer HY, Ranjan R: Valproic acid treatment of clozapine. induced myoclonus [Letter]. Am J Psychiatry 1994; 151:1246–1247
   PubMed Web of Science ®Google Scholar
• Kilian JG, Kerr K. Lawrence C, Celermajer DS: Myocarditis and cardioinyopathy associated with clozapine. Lancet 1999; 354:1841–1845
   PubMed Web of Science ®Google Scholar
• Lilleng P, Morild I, Hope M: Clozapine and myocarditis. Tidsskr Nor Laegeforen 1995; 115:293–294
   Google Scholar
• Meeker JE, Herrmann PW, Som CW. Reynolds PC: Clozap-ine tissue concentrations following an apparent overdose of clozaril. J Anal Toxicol 1992; 16:54–56
   Google Scholar
• Jensen VE, Gotzsche 0: Allergic myocarditis in clozapine treatment. Ugeskr Laeger 1994; 156:4151–4152
   PubMedGoogle Scholar
• Khalil N: Peri/myocarditis with clozapine (leponex). Psychi - atr Prax 1997; 24:46
   Google Scholar
• Bandelow B, Degner D. Kreusch U. Ruther E: Myocarditis under therapy with clozapine. Schizophr Res 1995; 17:293–294
   Google Scholar
• Walker AM, Lanza LL, Arellano F. Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1997; 8:671–677
   Google Scholar
• Leo RJ, Kreeger JL, Kim KY: Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30:603–605
   PubMedGoogle Scholar
• Hagg S. Spigset O, Soderstrom TG: Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155–1156
   PubMed Web of Science ®Google Scholar
• Wolstein J, Grohmann R. Ruther E, Hippius H: Antipsy-chotic drugs and venous thromboembolism [Correspon-dence]. Lancet 2000: 356:252
   PubMedGoogle Scholar
• Knudson if, Kortepeter C, Debitsky GM, Ahmad SR, Chen M: Antipsychotic drugs and venous thromboemolism [Cor-respondence]. Lancet 2000; 356:252–253
   Google Scholar
• Cleophas TJM, Kauw FHW: Pressor responses from noncar-dioselective beta-blockers. Angiology 1988; 39:587–596
   Google Scholar
• Testani M: Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994; 55:497–498
   Google Scholar
• Patterson TS: In: Yesavage 1, ed: Clozapine: A Compendium of Selected Readings. Stanford, CA: Sandoz Pharmaceuticals; 1992:136–138
   Google Scholar
• Thulesius O, Berlin E: Dihydroergotamine therapy in ortho-static hypotension due to psychotropic drugs. Int J Clin 'Ther Toxicol 1986; 24:465–467
   Google Scholar
• Rechlin T, Claus D, Weis M: Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994; 35:888–892
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: An atypical antipsychotic agent. Clin Pharmaco11989; 8:691–709
   PubMedGoogle Scholar
• Casey D: Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 (Suppl 11):40–45
   PubMed Web of Science ®Google Scholar
• Wetterling, T: Body weight gain with atypical antipsychotics-A comparative review. Drug Saf 2001; 24(1):59–73
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, Berisfor MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsy-chotics: Comparison of weight gain liabilities. J Clin Psychi-atry 1999; 60(6):358–363
   PubMed Web of Science ®Google Scholar
• Bustillo JR, Buchanan RW, Irish D, Breir A: Differential ef-fect of clozapine on weight: A controlled study. Am J Psychi-atry 1996; 153(6): 817–819
   PubMed Web of Science ®Google Scholar
• Leadbetter R. Shutty M, Pavalonis D, Vieeg V, Higgins P, Downs M: Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149(1):68–72
   Google Scholar
• Hummer M. Kemmler G, Kurz M, et al.: Weight gain induced by clozapine. Euro Neuropsychopharmacol 1995; 5:437–440
   Google Scholar
• Breefa D, Meehan T: Weight changes during clozapine treat-ment. Aust NZ J Psychiatry 1998; 32(5):718–721
   Google Scholar
• Wetterling T, IvIussigbrodt HE: Weight gain: Side effect of atypical neuroleptics'? J Clin Psychopharmacol 1999; 19(4): 316–321
   PubMed Web of Science ®Google Scholar
• Kraus T, Haack M. Schuld A, Scleh DH, Kuhn M. Uhp M, Polluacher T: Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am I Psychiatry 1999; 156(2):312–314
   Google Scholar
• George TP, Sernyak MJ, Ziedonis DM, Woods SW: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56(8):344–346
   PubMed Web of Science ®Google Scholar
• Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993–997
   PubMed Web of Science ®Google Scholar
• Umbricht DS, Pollack S. Kane JIVI: Clozapine and weight gain. J Clin Psychiatry 1994; 55(Suppl B) 5157–S160
   Google Scholar
• Willet WC, Manson JE, Stampler MJ. Colditz GA, Rosner B, Speizer FE, Hennekers CH: Weight, weight change, and coronary heart disease in women: Risk within the 'normal' weight range. JAMA 1995; 273: 461–465
   Google Scholar
• Fenton WS, Blyler CF. Heinssen PK: Determinants of med-ication compliance in schizophrenia: Empirical and clinical findings. Schizophr Bull 1997: 23: 637–651
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SN1, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–783
   PubMed Web of Science ®Google Scholar
• Uvnas-Moberg K, Ahlenius S. Alster P. Hillegaart V: Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagons in the rat. Neuroendocrinol-ogy 1996; 63:269–274
   Google Scholar
• Wozniak KM, Linnoila M: Hyperglycemic properties of sero-ton in receptor antagonists. Life Sci 1991; 49:101–109
   PubMed Web of Science ®Google Scholar
• Hayes G, Gibler B: Clozapine-induced constipation [Letter]. Am J Psychiatry 1998; 152:298
   Google Scholar
• Lennard-Jones JE: Clinical management of constipation. Pharmacology 1993; 47:216–223
   PubMed Web of Science ®Google Scholar
• Bourgeois JA, Drexler KG, Hall MJ: Hypersalivation and clozapine [Letter]. Hos Comm Psychiatry 1991; 42:1174
   PubMedGoogle Scholar
• Jann MW, Grimsley SR, Gray EC, Chang WH: Pharmaco-dynamics and pharmacokinetics of clozapine. Clinl Pharma-cokinet 1993; 24:161–176
   PubMed Web of Science ®Google Scholar
• Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW: Hepatotoxicity of clozapine. J Clin Psy-chopharmacol 1997; 17(4):314–317
   PubMed Web of Science ®Google Scholar
• Gaertner HJ, Fischer E, Hoss J: Side effects of clozapine. Psychopharmacologia 1989; (Suppl 99):597–S100
   Google Scholar
• Kellner M, Wiederrnann K, Krieg JC, Berg PA: Toxic hep-atitis by clozapine treatment [Letter]. Am J Psychiatry 1993; 150:985–986
   PubMed Web of Science ®Google Scholar
• Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brosen K: Clozapine-induced toxic hepatitis. Ugeskrift for Laeger 2001; 163(14):2013–2014. (In Danish)
   Google Scholar
• Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR: Hepatitis, hyperglycemia, pleural effesion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13(2):95–98
   PubMed Web of Science ®Google Scholar
• Dystonia and drug-induced hepatitis in a patient treated with clozapine [Letter]. Am J Psychiatry 1995; 152(4):647–648
   Google Scholar
• Thatcher GW, Cates M, Bair B: Clozaine-induced toxic hep-atitis [Letter]. Am J Psychiatry 1995; 152(2):296–297 -
   Google Scholar
• Sepulveda VAC, Lopez AE, Yanez LP, Ramirez CR, Escobar PB, Madrazo DGA: Sodium diphenylhydantoin as a probable cause of pancreatitis. Rev Gastroenterol Mex 1999; 64(4):186–189. (In Spanish)
   Google Scholar
• Bergemann N,Ehrig C. Diebold K, Mundt C, von Einsiedel R: Asymptomatic pancreatitis associated with clozapine. Phar-macopsychiatry 1999; 32(2):78–80
   Google Scholar
• Jubert P: Clozapine-related.pancreatitis [Letter]. Ann Intern Med 1994; 121(9):722–723
   Google Scholar
• Martin A: Acute pancreatitis associated with clozapine use [Letter]. Am J Psychiatry 1992; 149:714
   PubMed Web of Science ®Google Scholar
• Frankenburg -FR, Kando J: Eosinophilia, clozapine and pan-creatitis [Letter]. Lancet 1992; 340:251
   Google Scholar
• Davydov Liya, Botts SR: Clozapine-induced hypersalivation. Ann Pharmacother 2000; 34:662–665
   Google Scholar
• Robinson D, Fenn H, Yesavage J: Possible association of parotitis with clozapine. Am J Psychiatry 1995; 152:297–298
   PubMedGoogle Scholar
• Brodkin ES, Pelton GI-I, Price LH: Treatment of clozapine-induced parotid gland swelling [Letter]. Am J Psychiatry 1996; 153:445
   PubMedGoogle Scholar
• Vasile JS, Steingard S: Clozapine and the development of salivary gland swelling: A case study. J Clin Psychiatry 1995; 56:511–513
   PubMed Web of Science ®Google Scholar
• Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco /v1: Aspiration pneumonia possibly secondary to clonzapine-induced sialorrhea [Letter]. J Clin Psychopharmacol 1996; 16:462–463
   PubMed Web of Science ®Google Scholar
• Zorn SH, Jones SB, Ward KM, Liston DR: Clozapine is a potent and selective muscrinic My receptor agonist. Eur J Pharmacol 1994; 269:Rl-R2
   Google Scholar
• Szabadi E: Clozapine-induced hypersalivation [Letter]. Br J Psychiatry. 1997; 171:89
   Google Scholar
• Berlan M, IvIontastruc J-M, Lafontan M: Pharmacologi-cal prospects for alpha2-adrenoceptor antagonist therapy. Trends Pharmocol Sci 1992; 13:277–282
   PubMed Web of Science ®Google Scholar
• Pearlmen C. Clozapine, nocturnal sialorrhea, and chocking [Letter]. J Clin Psychopharmacol 1992; 12:69–70
   Google Scholar
• Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A: Trihexiphenidyl treatment of clozapine-induced hypersalivation. hit Clin Psychopharmocol 1997; 12:213–215
   PubMed Web of Science ®Google Scholar
• Copp PJ, Lament R, Tennent TO: Amitriptyline in clozapine-induced sialorrhea [Letter]. Br J Psychiatry 1991; 159:166
   PubMed Web of Science ®Google Scholar
• Grabowski J: Clonidine treatment of clozapine-induced hy-persalivation [Letter]. J Clin Psychopharmacol 1992; 12:69–70
   PubMed Web of Science ®Google Scholar
• Corrigan FM, MacDonald S, Reynolds GP: Clozapine-induced hypersalivation and the alpha2-adrenoceptor [Let-ter]. Br J Psychiatry 1995; 167:412
   PubMedGoogle Scholar
• Aronowitz JS, Safferman AZ, Lieberman JA: Management of clozapine induced enuresis [Letter]. Am .1 Psychiatry 1995; 152:472
   PubMed Web of Science ®Google Scholar
• Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE: Clozapine-induced urinary incontinence: Inci-dence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514–518
   PubMed Web of Science ®Google Scholar
• Steingard S: Use of desmopressin to treat clozapine-induced enuresis [Letter]. J Clin Psychiatry 1994; 55:325–326
   Google Scholar
• Richardson DW, Robinson AG: Desmopressin. Ann Intern Med 1985; 103:228–239
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Kando JC, Centorrino F, Gilbert JM: Blad-der dysfunction associated with clozapine therapy. J Clin Psy-chiatry 1996; 57:39–40
   Google Scholar
• Renwick AC, Renwick AG, Flanagan RJ, Femer RE: Moni-toring of clozapine and norclozapine plasma concentration-time curves in acute overdose. Clin Toxicol 2000; 38(3):325–328
   Google Scholar
• Meeker JE, Herrmann PW, Som CW, Reynolds PC: Cloza-pine tissue concentrations following apparent suicidal over-dose of clozariL .1 Anal Toxicol 1992; 16: 54–56
   Google Scholar
• Worm K, Birgitte K, Steentoft A: Clozapine cases with fatal, toxic or therapeutic concentrations. Int J Legal Med 1993; 106:115–118
   PubMed Web of Science ®Google Scholar
• Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J: Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxic-ity. Gastroenterology 1997; 112:1707–1709
   PubMedGoogle Scholar
• Panagiotis B: Grand mal seizures with liver toxicity in a case of clozapine treatment [Letter]. J Neuropsychiatry Clin Neu-rosci 1999; 11(1):117–118
   Google Scholar
• Schuster P, Gabriel E, Kufferle B, Strobl G, Karobath M: Re-versal by physostigmine of clozapine-induced delirium. Clin Toxicol 1977; 10(4):437–441
   PubMed Web of Science ®Google Scholar
• Ishii A, Mizoguchi K, Kageoka M. Seno H, Kumazawa T, Suzuki 0: Nonfatal suicidal intoxication by clozapine. Clin Toxicol 1997; 35(2):195–197
   Google Scholar
• Mady S, Wax P, Wang D, Goetz C, Hadley C, Love R: Pedi-atric clozapine intoxication. Am J Emerg Med 1996; 14:462–463
   PubMed Web of Science ®Google Scholar
• USP DI Drug Information for the Health care professional, Vol 1, 18th edn. Rockville, MD: United States Pharmacopeial Convention; 1998
   Google Scholar
• Physician's desk reference, 53rd edn. Montvale, NJ: Medical Economics; 1999
   Google Scholar
• Bamas C, Bergant A, Hummer M, Saria A, Fleischhacker WW: Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994; 151(6):945
   Google Scholar
• Waldman MD, Safferman AZ: Pregnancy and clozapine. Am J Psychiatry 1993; 150(1):168–169
   Web of Science ®Google Scholar
• Lieberman J. Safferman AZ: Clinical profile of clozapine: Ad-verse reactions and granulocytosis, in clozapine in treatment resistant schizophernia. A Scientific Update. Am J Psychia-try. 1993; 150(1):168–169
   Google Scholar
• Rice DP, Miller LS: The economic burden of schizo-phernia. Conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius, eds. schizophemia, Vol 1, Handbook of Mental Health Eco-nomics and Health Policy. New York: Wiley; 1996: 321–334
   Google Scholar
• Nightangle SA: Approval of clozapine for refractory schizo-phernia, JAMA 1990; 263:202
   Google Scholar
• Zito JM: Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clin North Am 1998; (20:181–202
   Google Scholar
• Zito 3M, Provenzaro G: Pharmaceutical decision mak-ing: Pharmaco epidemiology or pharmacoeconomics—Who's in the driver's seat? Psychopharmacol Bull 1996; 31: 735–744
   Google Scholar
• Revick DA, Luce BR, Weschler JM, Browns RE, Adler MA: Cost effectiveness of clozapine for treatment resistant schizo-phernia patients: Hosp Community Psychiatry 1990; 41: 850––854
   Google Scholar
• Rosenheck R, Cramer J, Xu W, Thomas 3, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozap-ine and haloperidol in hospitalized patient with refractory schizophernia outcome and cost. N Eng J Med 1997:337:809–815
   PubMed Web of Science ®Google Scholar